Evidence map›Paper›PMID 31856576›Full record

Trial reportAntiviral chemistry & chemotherapy

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.

Becky Jubb, Marilyn Lewis, Lynn McFadyen, Paul Simpson, Julie Mori, Phylinda Chan, Barry Weatherley, Elna van der Ryst, Mike Westby, Charles Craig

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antiviral chemistry & chemotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Becky JubbPfizer Inc, Clinical Group, Rare Disease, Groton, CT, USA.
Marilyn LewisPfizer Inc, Clinical Group, Rare Disease, Groton, CT, USA.
Lynn McFadyenPfizer Inc, Pharmacometrics, Sandwich, UK.
Paul SimpsonPfizer Inc, Clinical Group, Rare Disease, Groton, CT, USA.
Julie MoriPfizer Inc, Clinical Group, Rare Disease, Groton, CT, USA.
Phylinda ChanPfizer Inc, Pharmacometrics, Sandwich, UK.
Barry WeatherleyPfizer Inc, Pharmacometrics, Sandwich, UK.
Elna van der RystPfizer Inc, Clinical Group, Rare Disease, Groton, CT, USA.
Mike WestbyPfizer Inc, Clinical Group, Rare Disease, Groton, CT, USA.
Charles CraigPfizer Inc, Clinical Group, Rare Disease, Groton, CT, USA.ORCID 0000-0003-3276-9925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CCR5 Receptor AntagonistsHIV InfectionsMaravirocReceptors, CCR5Receptors, CXCR4CD4 Lymphocyte CountDouble-Blind MethodDrug Resistance, ViralHIV-1HumansPlacebosRNA, ViralCCR5 protein, humanCCR5 Receptor AntagonistsCXCR4 protein, humanMaravirocPlacebosReceptors, CCR5Receptors, CXCR4RNA, ViralAIDSdrug resistanceHIVmutations

Identifiers

PMID31856576
PMCPMC6931239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.